Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 13
1989 6
1990 4
1991 17
1992 9
1993 32
1994 22
1995 25
1996 24
1997 31
1998 48
1999 36
2000 40
2001 46
2002 48
2003 58
2004 41
2005 45
2006 65
2007 67
2008 69
2009 86
2010 74
2011 94
2012 95
2013 101
2014 81
2015 57
2016 56
2017 57
2018 33
2019 43
2020 28
2021 29
2022 28
2023 26
2024 31
2025 41
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,585 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, Du P, Qin S. Yin J, et al. Arch Gynecol Obstet. 2022 Dec;306(6):1891-1900. doi: 10.1007/s00404-022-06504-5. Epub 2022 Mar 19. Arch Gynecol Obstet. 2022. PMID: 35305140
BACKGROUND: There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregnancy. OBJECTIVE: To compare antihypertensive efficacy, pregnancy outcome and safety of amlodipine with nifedipine on hypertension duri …
BACKGROUND: There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregna …
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Elfaituri MK, Ghozy S, Ebied A, Morra ME, Hassan OG, Alhusseiny A, Abbas AS, Sherif NA, Fernandes JL, Huy NT. Elfaituri MK, et al. Vox Sang. 2021 Sep;116(8):887-897. doi: 10.1111/vox.13083. Epub 2021 Feb 26. Vox Sang. 2021. PMID: 33634883
Therefore, previous research has recommended amlodipine as an auxiliary treatment to current chelating agents for reducing iron overload in thalassaemia patients. ...Similarly, there was insignificant difference in cardiac T2* between amlodipine and control groups { …
Therefore, previous research has recommended amlodipine as an auxiliary treatment to current chelating agents for reducing iron overl …
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study).
Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, Nozato Y, Kario K, Rakugi H. Yamamoto K, et al. J Clin Hypertens (Greenwich). 2025 Jan;27(1):e14938. doi: 10.1111/jch.14938. Epub 2024 Dec 4. J Clin Hypertens (Greenwich). 2025. PMID: 39632589 Free PMC article. Clinical Trial.
The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24-h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. ...These results suggested that the blood pressure-lowering ef …
The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24-h SBP from baseline …
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H. Xie M, et al. Clin Cardiol. 2023 Aug;46(8):886-898. doi: 10.1002/clc.24082. Epub 2023 Jul 11. Clin Cardiol. 2023. PMID: 37432701 Free PMC article.
The results of the network meta-analysis showed that a total of 11 single-pill combination antihypertensive drugs were included, namely: Amlodipine/valsartan, Telmisartan/amlodipine, Losartan/HCTZ, Candesartan/HCTZ, Amlodipine/benazepril, Telmisartan/HCTZ, Va …
The results of the network meta-analysis showed that a total of 11 single-pill combination antihypertensive drugs were included, namely: …
Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis.
Gao Y, Zhou D, Yang P. Gao Y, et al. Ann Palliat Med. 2021 Oct;10(10):10768-10778. doi: 10.21037/apm-21-2455. Ann Palliat Med. 2021. PMID: 34763438 Free article.
Amlodipine treatment also significantly reduced the LV mass index. The mean difference (MD) between the follow-up and baseline LV mass index was -12.9; 95% CI: -15.4 to -10.4 (P<0.001). ...There was no significant decrease in the LV end-diastolic diameter following a …
Amlodipine treatment also significantly reduced the LV mass index. The mean difference (MD) between the follow-up and baseline LV mas …
Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis.
Luo Y, Ren L, Jiang M, Chu Y. Luo Y, et al. Rev Cardiovasc Med. 2019 Jun 30;20(2):91-98. doi: 10.31083/j.rcm.2019.02.31814. Rev Cardiovasc Med. 2019. PMID: 31345001 Free article.

Administration of amlodipine in the evening could significantly reduce the nighttime blood pressure (RR = 2.04, 95% CI 1.27-2.81, P < 0.00001), increased non-dipper alteration (RR = 0.51, 95% CI 0.41-0.63, P < 0.00001), and contained better anti-hypertension efficacy

…
Administration of amlodipine in the evening could significantly reduce the nighttime blood pressure (RR = 2.04, 95% CI 1.27-2.81, P & …
Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
Liu Y, Yan R, Song A, Niu X, Cao C, Wei J, Dong X, Gao D. Liu Y, et al. Am J Hypertens. 2014 Feb;27(2):268-78. doi: 10.1093/ajh/hpt210. Epub 2013 Dec 4. Am J Hypertens. 2014. PMID: 24304656
As compared with aliskiren/HCTZ, alikiren/amlodipine was associated with higher rate of therapeutic response (RR = 1.23; 95% CI = 1.14-1.33) and BP control (RR = 1.24; 95% CI = 1.11-1.39). Number of adverse events and withdrawals due to adverse events were similar with ali …
As compared with aliskiren/HCTZ, alikiren/amlodipine was associated with higher rate of therapeutic response (RR = 1.23; 95% CI = 1.1 …
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.
Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Böhm M, Mahfoud F. Vukadinović D, et al. J Hypertens. 2019 Oct;37(10):2093-2103. doi: 10.1097/HJH.0000000000002145. J Hypertens. 2019. PMID: 31107359
METHODS: We performed a meta-analysis by including all randomized, placebo-controlled trials reporting edema and headache with amlodipine in patients with arterial hypertension and CAD. Placebo-adjusted rate (%) was determined as follows: (SE amlodipine % - SE place …
METHODS: We performed a meta-analysis by including all randomized, placebo-controlled trials reporting edema and headache with amlodipine …
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C. Liu Y, et al. PLoS One. 2013 Jul 29;8(7):e70111. doi: 10.1371/journal.pone.0070111. Print 2013. PLoS One. 2013. PMID: 23922924 Free PMC article.
BACKGROUND: Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomi …
BACKGROUND: Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipi …
Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial.
Pratt K, Lordo R, Self S, Carlson L. Pratt K, et al. Am J Obstet Gynecol MFM. 2025 Jan;7(1):101575. doi: 10.1016/j.ajogmf.2024.101575. Epub 2024 Dec 9. Am J Obstet Gynecol MFM. 2025. PMID: 39662698 Clinical Trial.
Baseline demographics were similar between groups. Amlodipine had a non-inferior length of stay compared to nifedipine ER (Intent-to-Treat Wilcoxon pseudo-median amlodipine=73.5 hours, nifedipine ER=72.0 hours, 95% CI -8.00 to 6.00). ...Amlodipine was signifi …
Baseline demographics were similar between groups. Amlodipine had a non-inferior length of stay compared to nifedipine ER (Intent-to- …
1,585 results